Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma"
Haematologica
.
2018 Mar;103(3):e130.
doi: 10.3324/haematol.2017.186932.
Authors
Sophie Voruz
1
,
Filipe Martins
2
,
Anne Cairoli
2
,
Olaia Naveiras
2
,
Krisztian Homicsko
3
,
Edoardo Missiaglia
4
,
Laurence de Leval
4
,
Bettina Bisig
4
,
Olivier Michielin
3
,
Sabine Blum
2
Affiliations
1
Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland sophie.voruz@chuv.ch.
2
Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland.
3
Department of Oncology, University Hospital of Lausanne, Switzerland.
4
Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland.
PMID:
29491129
PMCID:
PMC5830398
DOI:
10.3324/haematol.2017.186932
No abstract available
Publication types
Comment
MeSH terms
Histiocytic Sarcoma
Humans
Imatinib Mesylate*
Protein-Tyrosine Kinases*
Pyridones
Pyrimidinones
Substances
Pyridones
Pyrimidinones
trametinib
Imatinib Mesylate
Protein-Tyrosine Kinases